How should we measure informed choice? The case of cancer screening
How should we measure informed choice? The case of cancer screening
复制标题
DOI：
10.1136/jme.2003.005793
复制
发表时间：
2005-04-01
影响因子：
4.1
通讯作者：
Weller, D
中科院分区：
文献类型：
--
作者：
Jepson, RG;Hewison, J;Weller, D
知情选择在支持患者自主权和确保人们不被欺骗或胁迫方面越来越被认为是重要的。在癌症筛查方面，重点已经从仅仅宣传筛查的好处转向提供全面的信息，使人们能够做出明智的选择。英国的癌症筛查计划现在有政策规定，他们有责任确保个人做出个人知情的选择。有必要评估这些政策是否意味着那些被邀请进行筛查的人正在做出知情的选择，以及全面的信息如何影响其他变量，如吸收，成本效益和满意度。目前，在癌症筛查中没有有效的知情选择措施。这样的措施可以用来评估干预措施的有效性，以增加知情选择和知情选择的水平，在人群中邀请筛查。它可以鼓励卫生专业人员负起责任。衡量癌症筛查知情选择的重要因素包括个人对筛查局限性的理解、自主选择的能力以及选择和行为之间的差异。
Informed choice is increasingly recognised as important in supporting patient autonomy and ensuring that people are neither deceived nor coerced. In cancer screening the emphasis has shifted away from just promoting the benefits of screening to providing comprehensive information to enable people to make an informed choice. Cancer screening programmes in the UK now have policies in place which state that it is their responsibility to ensure that individuals are making an individual informed choice. There is a need to evaluate whether such policies mean that those people invited for screening are making informed choices, and how comprehensive information affects other variables such as uptake, cost effectiveness, and satisfaction. At the present time, there is no validated measure of informed choice in cancer screening. Such a measure could be used to evaluate the effectiveness of interventions to increase informed choice and levels of informed choice in a population invited for screening. It could encourage health professionals to be accountable. Factors important when measuring informed choice in cancer screening include an individual's understanding of the limitations of screening, the ability to make an autonomous choice, and the difference between choice and behaviour.